Sanofi: US FDA approves Dupixent

(CercleFinance.com) - The US FDA has approved Dupixent (dupilumab) for the treatment of nodular prurigo in adults.


Dupixent becomes the first and only drug that is specifically indicated for the treatment of nodular prurigo in the US.

Nodular prurigo is a chronic, disabling dermatological disease with a type 2 inflammatory signature.

The FDA has granted priority review to Dupixent's application for the treatment of nodular prurigo - a status that is granted to drugs that have the potential to significantly improve the diagnosis, treatment or prevention of serious diseases.

Sanofi said, Dupixent has the potential to transform the gold standard treatment of nodular prurigo, alleviate its main symptoms, such as itching, and promote skin healing.


Copyright (c) 2022 CercleFinance.com. All rights reserved.